Tina J. Liu

CLOPIDOGREL – PROTON PUMP INHIBITOR DRUG INTERACTION Liu and Jackevicius 277

C. Jackevicius, Tina J. Liu, 2010 .

Eculizumab improves fatigue in refractory generalized myasthenia gravis

K. Patra, P. van Damme, M. Benatar, 2019, Quality of Life Research.

Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis

M. Benatar, M. Bromberg, M. Pasnoor, 2020, JAMA neurology.

Gluten Degradation, Pharmacokinetics, Safety, and Tolerability of TAK-062, an Engineered Enzyme to Treat Celiac Disease.

C. Wolf, I. S. Pultz, L. Saaby, 2021, Gastroenterology.

A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refactory B-Lineage Non-Hodgkin Lymphoma

R. Advani, B. Shah, Stella K. Kim, 2015 .

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

P. van Damme, M. Benatar, F. Piehl, 2019, Journal of the Neurological Sciences.

Highly polygenic architecture of antidepressant treatment response: Comparative analysis of SSRI and NRI treatment in an animal model of depression

M. Herbster, P. McGuffin, K. Bryson, 2016, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Drug Interaction Between Clopidogrel and Proton Pump Inhibitors

C. Jackevicius, Tina J. Liu, 2010, Pharmacotherapy.

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

P. van Damme, M. Benatar, F. Piehl, 2020, Journal of Neurology.